About
About Shionogi
Who we are
Heritage
Global affiliates and locations
Shionogi BV - tax strategy
Transparency
Investor Relations
Grants and Donations
Sustainability
Innovation
Innovation
Our areas of focus
Our Partners
Drug Discovery
Antimicrobial Resistance
News
Investors
Careers
Contact
Europe
Worldwide
HOME
News
2022
11
Xocova® (Ensitrelvir Fumaric Acid) Tablets 125mg Approved in Japan for the Treatment of SARS-CoV-2 Infection
Release
Medical News
2022/11/22
Xocova® (Ensitrelvir Fumaric Acid) Tablets 125mg Approved in Japan for the Treatment of SARS-CoV-2 Infection, under the Emergency Regulatory Approval System